相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019
William T. Cefalu et al.
DIABETES CARE (2019)
Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019
William T. Cefalu et al.
DIABETES CARE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
George Grunberger et al.
DIABETES THERAPY (2018)
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
George Grunberger et al.
DIABETES THERAPY (2018)
US Renal Data System 2017 Annual Data Report Epidemiology of Kidney Disease in the United States
Rajiv Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
Brendon L. Neuen et al.
CIRCULATION (2018)
Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial
Hiroyuki Takashima et al.
DIABETES & VASCULAR DISEASE RESEARCH (2018)
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and moderate renal function impairment: A systematic review and meta-analysis
Lin Zhang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMEA® randomised trial
Subodh Verma et al.
DIABETOLOGIA (2018)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2018 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2018)
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2018)
SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis
Samuel Seidu et al.
PRIMARY CARE DIABETES (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Christopher P. Cannon et al.
AMERICAN HEART JOURNAL (2018)
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
Subodh Verma et al.
CIRCULATION (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes
May-yun Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
Natalie A. Mordi et al.
BMJ OPEN (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study
Zhou Zhou et al.
DIABETES THERAPY (2017)
SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
Ashu Rastogi et al.
DIABETES THERAPY (2017)
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study
Zhou Zhou et al.
DIABETES THERAPY (2017)
SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
Ashu Rastogi et al.
DIABETES THERAPY (2017)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J. Jardine et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Trends in Prevalence of Chronic Kidney Disease in the United States
Daniel Murphy et al.
ANNALS OF INTERNAL MEDICINE (2016)
Glucagon and heart in type 2 diabetes: new perspectives
Antonio Ceriello et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
Paola Fioretto et al.
DIABETOLOGIA (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
Michael A. Weber et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Volker Vallon
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
Michael Roden et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2015)
Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
C. David Sjostrom et al.
DIABETES & VASCULAR DISEASE RESEARCH (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
William T. Cefalu et al.
DIABETOLOGIA (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Ilkka Tikkanen et al.
DIABETES CARE (2015)
A prospective two-center study on the associations between microalbuminuria, coronary atherosclerosis and long-term clinical outcome in asymptomatic patients with type 2 diabetes mellitus: evaluation by coronary CT angiography
Jin-Jin Kim et al.
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2015)
Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
Luca De Nicola et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
Sreeneeranj Kasichayanula et al.
CLINICAL PHARMACOKINETICS (2014)
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2014)
Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
Kaj Stenlof et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
J. Bolinder et al.
DIABETES OBESITY & METABOLISM (2014)
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
J. -F. Yale et al.
DIABETES OBESITY & METABOLISM (2014)
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
Josef Coresh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
The economic burden of progressive chronic kidney disease among patients with type 2 diabetes
Suma Vupputuri et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease
Szu-Chun Hung et al.
KIDNEY INTERNATIONAL (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
Anthony H. Barnett et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Epidemiology of Diabetes and Diabetes Complications in the Elderly: An Emerging Public Health Burden
Mark Corriere et al.
CURRENT DIABETES REPORTS (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
Muhammad Abdul-Ghani et al.
Endocrine Practice (2013)
Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus
Elizabeth M. Lamos et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Maryam Afkarian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes
Piero Ruggenenti et al.
DIABETES CARE (2012)
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
R. A. DeFronzo et al.
DIABETES OBESITY & METABOLISM (2012)
Health-related Quality of Life in CKD Patients: Correlates and Evolution over Time
Salim K. Mujais et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Antidiabetic Medication Use and Prevalence of Chronic Kidney Disease Among Patients With Type 2 Diabetes Mellitus in the United States
Carol E. Koro et al.
CLINICAL THERAPEUTICS (2009)
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
HC Gerstein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
分享论文
